Baidu
map

Aging:阜外医院牵头71万癌症患者随访研究:癌症合并高脂血症或有保护作用,合并心衰预后最差

2019-09-30 xujing 中国循环杂志

阜外医院杨进刚、袁建松和刘冬等近期发表的一项入选71万患者的大规模队列研究发现,18%的癌症患者有心血管危险因素或心血管疾病,明显高于一般人群。

阜外医院杨进刚、袁建松和刘冬等近期发表的一项入选71万患者的大规模队列研究发现,18%的癌症患者有心血管危险因素或心血管疾病,明显高于一般人群。

研究中,13.0%癌症患者至少有一种心血管病危险因素,5.0%患心血管病。

研究发现,最常见的危险因素是高血压(10.8%),尤其是前列腺癌和子宫癌患者高血压患病率达到了24.6%和20.6%。其次是糖尿病(5.3%)和血脂异常(1.2%)。

患病率最高的心血管疾病的是脑卒中(2.7%)、冠心病(1.7%)和心力衰竭(0.6%)。

研究还发现,在1,782,527人年(中位随访时间为2.5年)的随访中,有174482人死亡(24.6%)。

在调整年龄、性别、肿瘤分期和所接受的治疗后,合并心力衰竭的肿瘤患者预后最差,全因死亡风险增加79%;其次是心肌梗死,全因死亡风险增加50%。

合并房颤、脑卒中和糖尿病的患者死亡风险增加30%、21%和15%。

患血脂异常的癌症患者预后相对较好,死亡风险反而降低了27%,其是肺癌的生存有积极影响。但伴血脂异常的子宫颈癌全因死亡率却增加了180%。

研究者发现,心力衰竭在血液肿瘤中相对更为常见。

前列腺癌患者的心血管合并症的患病率最高(36.6%),其次是子宫癌(29.2%)、肾脏癌(27.5%)、胰腺癌(25.1%)和膀胱癌(24.0%)。



图1 按癌症类型划分的心血管共病患病情况

研究者还发现,随着年龄的增长,癌症患者会出现更多的心血管问题。



图2 按年龄组划分的心血管共病患病率

研究发现,与没有心血管病及危险因素的癌症患者(93.3/1000人)相比,合并心血管病和心血管病危险因素的癌症患者死亡率增加,分别为182.6/1000人年和109.5/1000人年。



图3 心血管危险因素和心血管疾病对一般癌症患者和前六大癌症类型患者死亡率的影响。

研究中最常见的六种癌症分别是肺癌(18.8%)、乳腺癌(24.4%)、宫颈癌(20.3%)、直肠癌(10.0%)、食道癌(8.3%)和癌(6.8%)。

研究中,癌症诊断的平均年龄(55.1±13.1)岁。16.7%的患者在癌症诊断时年龄小于45岁,4.9%的患者年龄小于35岁。

作者指出,由于中国癌症诊断时年龄相对较轻,合并心血管病危险因素和疾病的比例低于国外类似研究。

心力衰竭在血液系统肿瘤中相对更常见,这可能与血液肿瘤患者中的贫血、肾功能不全、淀粉样变性和与治疗有关的心血管毒性增加了心力衰竭的风险。

房颤与癌症之间也有密切的关系,这可能与慢性炎症、心血管危险因素和植物神经调节异常有关。

论文发表在衰老领域影响因子国际排名第一的《衰老(Aging)》杂志上。

原始出处:
Dong Liu, Zhiqiang Ma, Jingang Yang, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging(Albany NY). September 27, 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816128, encodeId=5cc31816128cd, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 10 20:04:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716547, encodeId=b4a71e16547ef, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sun Feb 02 02:04:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289650, encodeId=ba8d1289650fb, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293723, encodeId=113c1293e2364, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574650, encodeId=9e3f15e4650a4, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599123, encodeId=630c1599123a6, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373435, encodeId=0c353e343530, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Oct 02 06:32:20 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373398, encodeId=5d313e339818, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Oct 01 05:27:13 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816128, encodeId=5cc31816128cd, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 10 20:04:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716547, encodeId=b4a71e16547ef, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sun Feb 02 02:04:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289650, encodeId=ba8d1289650fb, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293723, encodeId=113c1293e2364, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574650, encodeId=9e3f15e4650a4, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599123, encodeId=630c1599123a6, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373435, encodeId=0c353e343530, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Oct 02 06:32:20 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373398, encodeId=5d313e339818, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Oct 01 05:27:13 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
    2020-02-02 habb
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816128, encodeId=5cc31816128cd, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 10 20:04:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716547, encodeId=b4a71e16547ef, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sun Feb 02 02:04:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289650, encodeId=ba8d1289650fb, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293723, encodeId=113c1293e2364, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574650, encodeId=9e3f15e4650a4, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599123, encodeId=630c1599123a6, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373435, encodeId=0c353e343530, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Oct 02 06:32:20 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373398, encodeId=5d313e339818, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Oct 01 05:27:13 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1816128, encodeId=5cc31816128cd, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 10 20:04:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716547, encodeId=b4a71e16547ef, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sun Feb 02 02:04:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289650, encodeId=ba8d1289650fb, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293723, encodeId=113c1293e2364, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574650, encodeId=9e3f15e4650a4, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599123, encodeId=630c1599123a6, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373435, encodeId=0c353e343530, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Oct 02 06:32:20 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373398, encodeId=5d313e339818, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Oct 01 05:27:13 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1816128, encodeId=5cc31816128cd, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 10 20:04:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716547, encodeId=b4a71e16547ef, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sun Feb 02 02:04:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289650, encodeId=ba8d1289650fb, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293723, encodeId=113c1293e2364, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574650, encodeId=9e3f15e4650a4, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599123, encodeId=630c1599123a6, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373435, encodeId=0c353e343530, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Oct 02 06:32:20 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373398, encodeId=5d313e339818, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Oct 01 05:27:13 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
    2019-10-02 pcw111
  6. [GetPortalCommentsPageByObjectIdResponse(id=1816128, encodeId=5cc31816128cd, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 10 20:04:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716547, encodeId=b4a71e16547ef, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sun Feb 02 02:04:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289650, encodeId=ba8d1289650fb, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293723, encodeId=113c1293e2364, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574650, encodeId=9e3f15e4650a4, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599123, encodeId=630c1599123a6, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373435, encodeId=0c353e343530, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Oct 02 06:32:20 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373398, encodeId=5d313e339818, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Oct 01 05:27:13 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1816128, encodeId=5cc31816128cd, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 10 20:04:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716547, encodeId=b4a71e16547ef, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sun Feb 02 02:04:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289650, encodeId=ba8d1289650fb, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293723, encodeId=113c1293e2364, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574650, encodeId=9e3f15e4650a4, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599123, encodeId=630c1599123a6, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373435, encodeId=0c353e343530, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Oct 02 06:32:20 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373398, encodeId=5d313e339818, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Oct 01 05:27:13 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
    2019-10-02 一个字-牛

    学习了谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1816128, encodeId=5cc31816128cd, content=<a href='/topic/show?id=fc4e9e348b6' target=_blank style='color:#2F92EE;'>#阜外医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97348, encryptionId=fc4e9e348b6, topicName=阜外医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 10 20:04:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716547, encodeId=b4a71e16547ef, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sun Feb 02 02:04:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289650, encodeId=ba8d1289650fb, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293723, encodeId=113c1293e2364, content=<a href='/topic/show?id=4c6e9e34931' target=_blank style='color:#2F92EE;'>#阜外医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97349, encryptionId=4c6e9e34931, topicName=阜外医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574650, encodeId=9e3f15e4650a4, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599123, encodeId=630c1599123a6, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Wed Oct 02 14:04:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373435, encodeId=0c353e343530, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Oct 02 06:32:20 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373398, encodeId=5d313e339818, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Oct 01 05:27:13 CST 2019, time=2019-10-01, status=1, ipAttribution=)]

相关资讯

Lancet:全球常见病发病率、相关住院治疗和相关死亡率差异研究

在35-70岁的成年人中,心血管疾病是全球死亡的主要原因

癌症取代心血管疾病成为发达国家的“头号杀手”

英国《柳叶刀》杂志最新刊登的两项大规模调查研究显示,癌症已经取代心血管疾病,成为发达国家民众的第一大死因。研究人员说,照此趋势,癌症将在未来几十年内成为全球范围内的“第一大健康杀手”。这两项研究调查了全球21个国家超过16万名对象。数据显示,死于癌症的人数是死于心血管疾病人数的两倍,癌症已成为发达国家人们面临的第一大健康威胁。研究分析,大约70%左右的心血管疾病都可以通过调节生活方式进行干预,比如

JAMA Oncology:二甲双胍抗癌实锤!临床试验证实,二甲双胍+靶向药一线治疗,可将携带EGFR突变晚期肺癌患者的生存期延长14个月

一项由墨西哥国立癌症研究所开展的临床II期试验证实,对存在EGFR突变的晚期肺腺癌患者,同时使用二甲双胍和靶向药进行一线治疗,可以将患者的生存期延长14个月!

JAMA Oncol:全新全球癌症数据——来看全球TOP10癌症!

近日,JAMA旗下子刊《JAMA Oncology》在线发表了最新的全球癌症地图,报告了2017年全球范围内195个国家/地区、29组癌症的发病率、死亡率、伤残调整寿命年(DALYs)等数据信息。

JAMA Oncol:免疫治疗前使用抗生素,或显著降低癌症患者的生存率

近日一项研究发现,接受免疫治疗的癌症患者如果近期使用过抗生素的话,病情将更加糟糕,并导致其治疗效果和生存率显着下降。

Baidu
map
Baidu
map
Baidu
map